Patents by Inventor Florian Montel

Florian Montel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DIFLUOROMETHYL-PYRIDIN-2-YL TRIAZOLES
    Publication number: 20230286946
    Abstract: The present invention relates to difluoromethyl-pyridin-2-yl triazoles of general formula (I) which are modulators of GABAA receptors containing the ?5 subunit, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for the manufacture of compounds according to the invention.
    Type: Application
    Filed: August 4, 2021
    Publication date: September 14, 2023
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Florian Montel, Yunhai Cui, Niklas Heine, Oliver Hucke, Radoslaw Lipinski, Stefan Peters, Janus Schreiber Larsen
  • DIFLUOROMETHYL-PHENYL TRIAZOLES
    Publication number: 20210147393
    Abstract: The present invention relates to difluoromethyl-phenyl triazoles of general formula (1) which are modulators of GABAA receptors containing the ?5 subunit, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Application
    Filed: January 27, 2021
    Publication date: May 20, 2021
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Janus Schreiber Larsen, Florian Binder, Yunhai Cui, Oliver Hucke, Radoslaw Lipinski, Florian Montel, Markus Ostermeier, Alexandre Perera, Stefan Peters
  • COMT Inhibiting Methods and Compositions
    Publication number: 20210139479
    Abstract: This invention relates to compounds, pharmaceutical compositions and their use for treating neuropsychiatric and neurodegenerative disorders. In particular, the invention relates to inhibitors of catechol-O-methyltransferase and their use as therapeutics for central nervous system disease.
    Type: Application
    Filed: January 22, 2021
    Publication date: May 13, 2021
    Inventors: James Barrow, Glen Ernst, Dominique Swinnen, Florian Montel, Sabine Defays, Yifeng Huang, Pablo de Leon, Michael Steven Poslusney
  • Difluoromethyl-phenyl triazoles
    Patent number: 10941137
    Abstract: The present invention relates to difluoromethyl-phenyl triazoles of general formula (I) which are modulators of GABAA receptors containing the ?5 subunit, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: March 9, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Janus Schreiber Larsen, Florian Binder, Yunhai Cui, Oliver Hucke, Radoslaw Lipinski, Florian Montel, Markus Ostermeier, Alexandre Perera, Stefan Peters
  • COMT inhibiting methods and compositions
    Patent number: 10934283
    Abstract: Compounds that inhibit COMT enzyme and pharmaceutical compositions comprising the same are provided herein. Methods of treating various psychiatric and neurological disorders with the compounds and pharmaceutical compositions described herein are also provided.
    Type: Grant
    Filed: November 25, 2016
    Date of Patent: March 2, 2021
    Assignee: LIEBER INSTITUTE, INC.
    Inventors: James Barrow, Glen Ernst, Dominique Swinnen, Florian Montel, Sabine Defays, Yifang Huang, Pablo de León, Michael Steven Poslusney
  • DIFLUOROMETHYL-PHENYL TRIAZOLES
    Publication number: 20200024261
    Abstract: The present invention relates to difluoromethyl-phenyl triazoles of general formula (I) which are modulators of GABAA receptors containing the ?5 subunit, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Application
    Filed: July 19, 2019
    Publication date: January 23, 2020
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Janus Schreiber Larsen, Florian Binder, Yunhai Cui, Oliver Hucke, Radoslaw Lipinski, Florian Montel, Markus Ostermeier, Alexandre Perera, Stefan Peters
  • COMT Inhibiting Methods and Compositions
    Publication number: 20180305354
    Abstract: Compounds that inhibit COMT enzyme and pharmaceutical compositions comprising the same are provided herein. Methods of treating various psychiatric and neurological disorders with the compounds and pharmaceutical compositions described herein are also provided.
    Type: Application
    Filed: November 25, 2016
    Publication date: October 25, 2018
    Inventors: James Barrow, Glen Ernst, Dominique Swinnen, Florian Montel, Sabine Defays, Yifang Huang, Pablo de LEÓN, Michael Steven Poslusney
  • Compounds for enhancing the cognitive function
    Patent number: 9630948
    Abstract: The invention relates to 2-oxo-1-pyrrolidinyl triazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals for enhancing the cognitive function or to counteract cognitive decline.
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: April 25, 2017
    Assignee: UCB Pharma, S.A.
    Inventors: Florian Montel, Eric Jnoff
  • Methods for Treating Parkinson's Disease
    Publication number: 20160367560
    Abstract: The invention pertains to a method of treating Parkinson's disease (PD) in a mammal, comprising administering a first pharmaceutical agent and a second pharmaceutical agent, wherein the first pharmaceutical agent is an antagonist of the adenosine receptor 2 (A2A) and the second pharmaceutical agent is an antagonist of the N-methyl-D-aspartate (NMDA) receptor subtype NR2B.
    Type: Application
    Filed: June 17, 2016
    Publication date: December 22, 2016
    Inventors: Anne Michel, Patrick Downey, Florian Montel, Dieter Scheller, Bernard Christophe
  • Methods for treating Parkinson's disease
    Patent number: 9387212
    Abstract: The invention pertains to a method of treating Parkinson's disease (PD) in a mammal, comprising administering a first pharmaceutical agent and a second pharmaceutical agent, wherein the first pharmaceutical agent is an antagonist of the adenosine receptor 2 (A2A) and the second pharmaceutical agent is an antagonist of the N-methyl-D-aspartate (NMDA) receptor subtype NR2B.
    Type: Grant
    Filed: April 19, 2013
    Date of Patent: July 12, 2016
    Assignee: UCB Biopharma SPRL
    Inventors: Anne Michel, Patrick Downey, Florian Montel, Dieter Scheller, Bernard Christophe
  • Compounds for Enhancing the Cognitive Function
    Publication number: 20160185761
    Abstract: The invention relates to 2-oxo-1-pyrrolidinyl triazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals for enhancing the cognitive function or to counteract cognitive decline.
    Type: Application
    Filed: July 28, 2014
    Publication date: June 30, 2016
    Applicant: UCB Pharma, S.A.
    Inventors: Florian Montel, Eric Jnoff
  • 2-oxo-piperidinyl derivatives
    Patent number: 9067930
    Abstract: The present invention relates to 2-oxo-piperidinyl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
    Type: Grant
    Filed: October 10, 2012
    Date of Patent: June 30, 2015
    Assignee: UCB Pharma, S.A.
    Inventors: Ali Ates, Florian Montel, Anne Valade, Olivier Lorthioir
  • Methods for Treating Parkinson's Disease
    Publication number: 20150157638
    Abstract: The invention pertains to a method of treating Parkinson's disease (PD) in a mammal, comprising administering a first pharmaceutical agent and a second pharmaceutical agent, wherein the first pharmaceutical agent is an antagonist of the adenosine receptor 2 (A2A) and the second pharmaceutical agent is an antagonist of the N-methyl-D-aspartate (NMDA) receptor subtype NR2B.
    Type: Application
    Filed: April 19, 2013
    Publication date: June 11, 2015
    Inventors: Anne Michel, Patrick Downey, Florian Montel, Dieter Scheller, Bernard Christophe
  • 2-Oxo-Piperidinyl Derivatives
    Publication number: 20150011526
    Abstract: The present invention relates to 2-oxo-piperidinyl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
    Type: Application
    Filed: October 10, 2012
    Publication date: January 8, 2015
    Inventors: Ali Ates, Florian Montel, Anne Valade, Olivier Lorthioir